Publications
Found 3 results
Filters: Author is J.N. Zhang [Clear All Filters]
“Intracranial aneurysm risk factor genes: relationship with intracranial aneurysm risk in a Chinese Han population”, vol. 14, pp. 6865-6878, 2015.
, “Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226”, vol. 14, pp. 13588-13594, 2015.
, “Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma”, vol. 11, pp. 3618-3628, 2012.
,
Bai J, Dai J, Yu H, Shen H, et al. (2009). Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J. Toxicol. Environ. Health A 72: 677-682.
http://dx.doi.org/10.1080/15287390902840930
PMid:19492228
Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
http://dx.doi.org/10.2307/2533446
PMid:7786990
Biernat W, Kleihues P, Yonekawa Y and Ohgaki H (1997). Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56: 180-185.
http://dx.doi.org/10.1097/00005072-199702000-00009
PMid:9034372
Bond GL, Hu W, Bond EE, Robins H, et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
http://dx.doi.org/10.1016/j.cell.2004.11.022
PMid:15550242
Bredel M, Scholtens DM, Yadav AK, Alvarez AA, et al. (2011). NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364: 627-637.
http://dx.doi.org/10.1056/NEJMoa1006312
PMid:21175304
Dai S, Mao C, Jiang L, Wang G, et al. (2009). P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum. Genet. 125: 633-638.
http://dx.doi.org/10.1007/s00439-009-0664-3
PMid:19357867
DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188.
http://dx.doi.org/10.1016/0197-2456(86)90046-2
Dumont P, Leu JI, Della Pietra AC, George DL, et al. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33: 357-365.
http://dx.doi.org/10.1038/ng1093
PMid:12567188
Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
http://dx.doi.org/10.1136/bmj.315.7109.629
PMid:9310563 PMCid:2127453
El Hallani S, Marie Y, Idbaih A, Rodero M, et al. (2007). No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J. Neurooncol. 85: 241-244.
http://dx.doi.org/10.1007/s11060-007-9416-1
PMid:17568997
El Hallani S, Ducray F, Idbaih A, Marie Y, et al. (2009). TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 72: 332-336.
http://dx.doi.org/10.1212/01.wnl.0000341277.74885.ec
PMid:19171829
Fang F, Yu XJ, Yu L and Yao L (2011). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med. Oncol. 28: 981-985.
http://dx.doi.org/10.1007/s12032-010-9577-1
PMid:20503107
Gu J, Liu Y, Kyritsis AP and Bondy ML (2009). Molecular epidemiology of primary brain tumors. Neurotherapeutics 6: 427-435.
http://dx.doi.org/10.1016/j.nurt.2009.05.001
PMid:19560733
Haupt Y, Maya R, Kazaz A and Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
http://dx.doi.org/10.1038/387296a0
PMid:9153395
Hunter SB, Abbott K, Varma VA, Olson JJ, et al. (1995). Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J. Neuropathol. Exp. Neurol. 54: 57-64.
http://dx.doi.org/10.1097/00005072-199501000-00007
PMid:7815080
Idbaih A, Boisselier B, Marie Y, Sanson M, et al. (2008). Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 1198: 16-20.
http://dx.doi.org/10.1016/j.brainres.2008.01.027
PMid:18262501
Jeong BS, Hu W, Belyi V, Rabadan R, et al. (2010). Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J. 24: 1347-1353.
http://dx.doi.org/10.1096/fj.09-146001
PMid:20019240
Jha P, Jha P, Pathak P, Chosdol K, et al. (2011). TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp. Mol. Pathol. 90: 167-172.
http://dx.doi.org/10.1016/j.yexmp.2010.11.002
PMid:21115003
Khatri RG, Navaratne K and Weil RJ (2008). The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. J. Neurosurg. 109: 842-848.
http://dx.doi.org/10.3171/JNS/2008/109/11/0842
PMid:18976073
Kubbutat MH, Jones SN and Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature 387: 299-303.
http://dx.doi.org/10.1038/387299a0
PMid:9153396
Kussie PH, Gorina S, Marechal V, Elenbaas B, et al. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
http://dx.doi.org/10.1126/science.274.5289.948
PMid:8875929
Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, et al. (2008). TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet. Cytogenet. 180: 14-19.
http://dx.doi.org/10.1016/j.cancergencyto.2007.08.019
PMid:18068527
Liu L, Wang K, Zhu ZM and Shao JH (2011). Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Arch. Med. Res. 42: 60-69.
http://dx.doi.org/10.1016/j.arcmed.2011.01.008
PMid:21376265
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114: 97-109.
http://dx.doi.org/10.1007/s00401-007-0243-4
PMid:17618441 PMCid:1929165
Malmer B, Feychting M, Lonn S, Ahlbom A, et al. (2005). p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol. Biomarkers Prev. 14: 2220-2223.
http://dx.doi.org/10.1158/1055-9965.EPI-05-0234
PMid:16172235
Malmer BS, Feychting M, Lonn S, Lindstrom S, et al. (2007). Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J. Neurooncol. 82: 229-237.
http://dx.doi.org/10.1007/s11060-006-9275-1
PMid:17151932
Marin MC, Jost CA, Brooks LA, Irwin MS, et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25: 47-54.
http://dx.doi.org/10.1038/75586
PMid:10802655
Minelli C, Thompson JR, Abrams KR, Thakkinstian A, et al. (2008). How should we use information about HWE in the meta-analyses of genetic association studies? Int. J. Epidemiol. 37: 136-146.
http://dx.doi.org/10.1093/ije/dym234
PMid:18037675
Ohgaki H, Dessen P, Jourde B, Horstmann S, et al. (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64: 6892-6899.
http://dx.doi.org/10.1158/0008-5472.CAN-04-1337
PMid:15466178
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, et al. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860.
http://dx.doi.org/10.1038/362857a0
PMid:8479525
Parhar P, Ezer R, Shao Y, Allen JC, et al. (2005). Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res. Mol. Brain Res. 137: 98-103.
http://dx.doi.org/10.1016/j.molbrainres.2005.02.016
PMid:15950766
Pinto GR, Yoshioka FK, Silva RL, Clara CA, et al. (2008). Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet. Mol. Res. 7: 207-216.
http://dx.doi.org/10.4238/vol7-1gmr415
PMid:18393224
Rajaraman P, Wang SS, Rothman N, Brown MM, et al. (2007). Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol. Biomarkers Prev. 16: 1655-1661.
http://dx.doi.org/10.1158/1055-9965.EPI-07-0314
PMid:17684142
Shete S, Hosking FJ, Robertson LB, Dobbins SE, et al. (2009). Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41: 899-904.
http://dx.doi.org/10.1038/ng.407
PMid:19578367
Suzuki SO and Iwaki T (2000). Amplification and overexpression of mdm2 gene in ependymomas. Mod. Pathol. 13: 548-553.
http://dx.doi.org/10.1038/modpathol.3880095
PMid:10824927
Tsuiki H, Nishi T, Takeshima H, Yano S, et al. (2007). Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis. Neurol. Med. Chir. 47: 203-208.
http://dx.doi.org/10.2176/nmc.47.203
Wang LE, Bondy ML, Shen H, El-Zein R, et al. (2004). Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 64: 5560-5563.
http://dx.doi.org/10.1158/0008-5472.CAN-03-2181
PMid:15313891
Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, et al. (2005). The molecular epidemiology of gliomas in adults. Neurosurg. Focus 19: E5.
http://dx.doi.org/10.3171/foc.2005.19.5.6
PMid:16398469
Wrensch M, Jenkins RB, Chang JS, Yeh RF, et al. (2009). Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41: 905-908.
http://dx.doi.org/10.1038/ng.408
PMid:19578366 PMCid:2923561
Yang M, Guo Y, Zhang X, Miao X, et al. (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28: 1996-2001.
http://dx.doi.org/10.1093/carcin/bgm168
PMid:17638920
Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486.
http://dx.doi.org/10.1002/ijc.22833
PMid:17546594